Trial · NCT02667496
Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
NCT02667496, Phase 2, Withdrawn, Sanofi
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease. Trials, record NCT02667496. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02667496
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
- NCT number
- NCT02667496
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Sanofi
- Conditions
- Dementia Alzheimer's Type
- Interventions
- Sargramostim GZ402664, Placebo, Florbetapir F18
- First posted
- 2016-01-29
- Last updated
- 2017-04-07
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in standardized uptake value ratio as measured by PET using florbetapir F18 (Amyvid) | From baseline to Week 24 | |
| Secondary | Number of patients experiencing treatment-emergent adverse events (TEAEs) | Week 24 | |
| Secondary | Change from baseline in CSF analysis | Prior to first injection on Day 1 to serve as a baseline for any necessary follow-up, and optional assessment at Day 155 | |
| Secondary | MRI to assess for emergence of amyloid related imaging abnormalities (ARIA) | At Screening and Days 43, 85, and 155 | |
| Secondary | Measurement of antidrug antibody levels | At Days 1, 29, 57, 85, and 155 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| UF1AG046143 | A Proof of Concept Study Examining The Safety and Efficacy of Innate Immune Syste | HAGINO, OWEN | SANOFI AVENTIS U S, INC. | NATIONAL INSTITUTE ON AGING | 2013 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02667496
GET https://conductscience.org/api/trials/v1/NCT02667496/registered